Applied Therapeutics Inc

NASDAQ:APLTUnited States

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Contact Information

Headquarters

545 FIFTH AVENUE, SUITE 1400NEW YORK, NY, United States 10017

Phone

212-220-9226

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Founder

Shoshana Shendelman

Chief Financial Officer and Principal Financial Officer, Director

Leslie Funtleyder

Chief Operating Officer and Chief Business Officer

Constantine Chinoporos

Interim Principal Financial Officer, Chief Accounting Officer

Catherine Thorpe

Chief Commercial Officer

Dale Hooks